Pharmaceutical Executive, Sep 1, 2012 - Pharmaceutical Executive

ADVERTISEMENT
Pharmaceutical Executive, Sep 1, 2012
Features
The Big Sell: Biologics In Emerging Markets
By Thomas Baker
High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell.
The Payer C Change: From Customers to Competitors
By Stan Bernard, MD
"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."
Pharm Exec's 11th Annual Industry Audit
By Bill Trombetta
Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.
Column
The Power of Patient Feedback
By Ben Comer
Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. Patient voices are increasing in volume, along with their roles in treatment decisions.
Costs, Coverage, and Court Decisions
By Jill Wechsler
Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
The Endless Treadmill of End-of-Life Care
By Robin Hertz
Bending the cost curve back to valuing the cycle of life.
Doctors' Words No Longer Gospel
By Al Topin
In the digital age, physicians don't call the shots when it comes to healthcare guidance, writes Al Topin.
Open Innovation in Pharma: Defining the Dialogue
By Roy F. Waldron
There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?
Patients Wade Into the Pricing Debate
By Reflector
Europe's fiscal crisis is becoming a new rallying cry for patient groups—but regional unity is still elusive.
From the Editor
The Margin Call
By William Looney
Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

ADVERTISEMENT

Click here